CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia

T-cell prolymphocytic leukemia (T-PLL) is a poor prognostic disease with very limited options of efficient therapies. Most patients are refractory to chemotherapies and despite high response rates after alemtuzumab, virtually all patients relapse. Therefore, there is an unmet medical need for novel...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Biomark Res
Main Authors: Cuesta-Mateos, Carlos, Fuentes, Patricia, Schrader, Alexandra, Juárez-Sánchez, Raquel, Loscertales, Javier, Mateu-Albero, Tamara, Vega-Piris, Lorena, Espartero-Santos, Marina, Marcos-Jimenez, Ana, Sánchez-López, Blanca Andrea, Pérez-García, Yaiza, Jungherz, Dennis, Oberbeck, Sebastian, Wahnschaffe, Linus, Kreutzman, Anna, Andersson, Emma I., Mustjoki, Satu, Faber, Edgar, Urzainqui, Ana, Fresno, Manuel, Stamatakis, Kostantino, Alfranca, Arantzazu, Terrón, Fernando, Herling, Marco, Toribio, María Luisa, Muñoz-Calleja, Cecilia
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Rapid Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7585232/
https://ncbi.nlm.nih.gov/pubmed/33110606
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00234-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados